Related Experiment Video
Updated: Jun 18, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
New developments in antiviral therapy for chronic hepatitis B.
R B Takkenberg1, C J Weegink, H L Zaaijer
1AMC Liver Center, Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. r.b.takkenebrg@amc.nl
Vox Sanguinis
|December 3, 2009
Summary
Chronic hepatitis B impacts millions globally. Current treatments aim to suppress the virus, but new strategies focus on achieving HBsAg loss for a potential cure.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis B (CHB) affects 400 million worldwide, causing liver cirrhosis and hepatocellular carcinoma (HCC).
- Recent advancements have improved CHB management, leading to more patients achieving inactive disease states.
- Existing treatments include peginterferon (peg-IFN) and nucleos(t)ide analogues, aiming to suppress hepatitis B virus (HBV) DNA.
Purpose of the Study:
- To review current treatment strategies for CHB, including their response rates.
- To discuss the limitations of existing therapies, such as adverse effects and drug resistance.
- To explore future treatment directions focused on achieving HBsAg loss and anti-HBs conversion for a potential cure.
Main Methods:
- Literature review of long-term peg-IFN trials.
- Analysis of response markers for predicting treatment outcomes.
- Discussion of emerging strategies targeting the HBV life cycle.
Main Results:
- Peginterferon (peg-IFN) and nucleos(t)ide analogues are current mainstays for CHB treatment.
- Peg-IFN can cause adverse effects, while nucleos(t)ide analogues may lead to drug resistance.
- No novel compounds directly targeting the HBV life cycle are currently in late-stage development.
Conclusions:
- Current treatments aim to suppress HBV DNA and prevent liver disease progression.
- Achieving HBsAg loss and anti-HBs conversion represents the closest therapeutic goal to a cure for CHB.
- Future research should focus on developing novel therapies that achieve functional cures for chronic hepatitis B.
Related Concept Videos
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...